MECHANISMS OF HYPERTENSION FOLLOWING VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: THE HYPAZ TRIAL

Vascular endothelial growth factor (VEGF) promotes nitric oxide activity. VEGF inhibitors are anti-cancer drugs that often cause hypertension but mechanisms are unclear. We hypothesised that VEGF inhibition leads to endothelial dysfunction, thus increasing blood pressure. 27 normotensive cancer